NasdaqGS:EWTXPharmaceuticals
Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy?
Earlier this week, Edgewise Therapeutics used its presentation at the 44th J.P. Morgan Healthcare Conference to outline 2026 milestones, including pivotal GRAND CANYON data for sevasemten in Becker muscular dystrophy, Phase 2 readouts for EDG-7500 in hypertrophic cardiomyopathy, and continued development of its early-stage heart failure candidate EDG-15400.
A distinctive aspect of the update is Edgewise’s attempt to build an integrated neuromuscular and cardiovascular franchise, with...